Literature DB >> 1120486

Optimal statistical design of radioimmunoassays and competitive protein-binding assays.

P C Chang, R T Rubin, M Yu.   

Abstract

The statistical analysis of radioimmunoassay and competitive protein binding assay data is complex. Because the response variable (percent counts) is not lineraly related to log dose, a logit transformation of the response variable usually is performed to permit linear regression analysis. This transformation induces marked heterogeneity of variance, so that iterative weighted regression programs have been used to achieve the best standard curve and the most precise dose estimates of unknowns. In this study several parameters of assay design are investigated in order to establish those designs yielding antigen concentration estimates of highest precision as well as estimates of comparable precision by either simple linear regression analysis or by the more complex weighted regression technique. Unknown estimates of highest precision are obtained when 1) the present counts of the standard doses covers a range of approximately 80 percent to 20 percent, 2) the number of standard dose levels is eight or more, 3) the number of replicates at each dose level is two or more, and 4) the percent counts of the unknowns also are within the range 80 percent ot 20 percent. Under these conditions, also, simple linear regression yields unknown estimates of comparable precision to weighted regression and therefore may be safely used.

Mesh:

Substances:

Year:  1975        PMID: 1120486     DOI: 10.1210/endo-96-4-973

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  2 in total

1.  Factor IX antigen by radioimmunoassay. Abnormal factor IX protein in patients on warfarin therapy and with hemophilia B.

Authors:  A R Thompson
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

2.  Metallothionein: structure/antigenicity and detection/quantitation in normal physiological fluids.

Authors:  J S Garvey
Journal:  Environ Health Perspect       Date:  1984-03       Impact factor: 9.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.